Login / Signup

Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study.

Xueyan ShanShiyu WuXixia ChenYongpeng Ge
Published in: Seminars in arthritis and rheumatism (2024)
JAKi were effective in most refractory ASS patients as evidenced by improved skin rash, myositis, and ILD. However, larger prospective controlled studies are required to evaluate its efficacy.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • protein kinase
  • cell therapy
  • replacement therapy